$JAZZ News

JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $300

Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine

Jazz Pharmaceuticals Estimates $755M Pre-Tax Acquired IPR&D Charge From Actio Biosciences Acquisition; Expected $11.00 Negative Impact On Both GAAP And Adjusted EPS In Q3 2026

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026

Jazz Pharmaceuticals Presents Data From Its Phase 3 HERIZON-GEA-01 Study Of Ziihera In Combination With Chemotherapy At ESMO Congress 2026 To Treat Patients With HER2-Positive Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $314

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026

Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?

Ziihera’s FDA Win and Leadership Change Might Change The Case For Investing In Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story

Jazz Pharmaceuticals gets Cramer's vote of confidence

Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $296

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

CNBC's Becky Quick to Moderate CEO Leadership Dialogue on the Next Decade of Rare Disease at the NORD Breakthrough Summit

Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks

Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target

Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B

Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?